Skip to main content
padlock icon - secure page this page is secure

Identification of an HLA-A2-restricted CD147 epitope that can induce specific CTL cytotoxicity against drug resistant MCF-7/Adr cells

Buy Article:

$42.00 + tax (Refund Policy)

Cluster of differentiation (CD)147 is highly expressed in drug-resistant tumor cell lines and is involved in the formation of tumor drug resistance. Therefore, immunotherapy utilizing CD147 epitope peptides is a promising approach for the elimination of drugresistant tumor cells. However, like most tumorassociated antigens (TAAs), CD147 belongs to the autoantigen category, and T cells that recognize high affinity, immunodominant epitopes from autoantigens are deleted though thymic negative selection. Furthermore, wildtype autoantigen peptides cannot effectively activate and expand T lymphocytes with lower affinity T cell receptors in vivo. However, mutations of TAA peptides have been demonstrated to increase the affinity of major histocompatibility complex molecules and their binding to T cell receptor molecules, leading to activation of T lymphocytes in vitro. In the present study, a highaffinity point mutation peptide, CD147126134L2, was predicted by the human leukocyte antigen (HLA) binding prediction algorithm and its affinity was testified using a T2 binding assay. In addition, when peptidespecific cytotoxic T lymphocytes (CTLs) were stimulated with dendritic cells loaded with the CD147126134L2 peptide under HLAA*02:01 restriction, interferonγ release and cytotoxicity assays showed that peptidespecific CTLs effectively crossrecognized and lysed T2 target cells loaded either with the wildtype (CD147126134) or mutated peptide (CD147126134L2). Moreover, the CD147126134L2 peptidespecific CTLs exerted strong cytotoxic activity against drugresistant MCF7/Adr cells, which express a high level of CD147 and are HLAA*02:01positive, but not against normal MCF7 cells. Thus, this suggests that the wildtype peptide (CD147126134) is naturally presented on HLAA*02:01 of CD147expressing MCF7/Adr cells and is crossrecognized by CTLs. In conclusion, an HLAA*02:01restricted CD147point mutant epitope peptide was identified that induces CTLs to efficiently lyse drugresistant MCF7 cells that highly express CD147. Therefore, this immunotherapeutic approach should be explored as a potential treatment for drug-resistant tumors.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics

Document Type: Research Article

Affiliations: Guangdong Province Key Laboratory of Biotechnology Drug Candidates, Guangdong Pharmaceutical University, Guangzhou, Guangdong 510006, P.R. China

Publication date: April 1, 2018

More about this publication?
  • Oncology Letters is a monthly, peer-reviewed journal, available in print and online, that focuses on all aspects of clinical oncology, as well as in vitro and in vivo experimental model systems relevant to the mechanisms of disease.

    The principal aim of Oncology Letters is to provide the prompt publication of original studies of high quality that pertain to clinical oncology, chemotherapy, oncogenes, carcinogenesis, metastasis, epidemiology and viral oncology in the form of original research, reviews and case reports.
  • Editorial Board
  • Information for Authors
  • Submit a Paper
  • Subscribe to this Title
  • Information for Advertisers
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more